Literature DB >> 20009448

[Clinical utility of PET-CT for esophageal cancer].

Yoshinori Fujiwara1, Nobuaki Kaibe, Tomohiro Matsumoto, Hidetaka Yamashita, Kenji Koishi, Shojirou Kikuchi, Mitsuru Sasako, Shuji Kawata, Naohiko Oku, Thoru Kashiwagi.   

Abstract

It is important to diagnose the exact clinical staging according to the improvement of treatment for esophageal cancer. PET examinations for esophageal cancer are now covered by Japanese government health insurance, so the number of PET scans is now gradually increased in many institutions and their utility has been reported. In this report, we reviewed the conventional diagnostic tools for esophageal cancer and evaluated the clinical significance of PET-scans conventionally associated with it. The depth of tumor invasion of a primary tumor is detectable in more than 80% of cases of SM2 or deeper invasion. With lymph node metastasis, the sensitivity was 66. 7% and specificity 93. 5%. With distant metastasis, there is reportedly a high detection rate in bone metastasis and liver metastasis. However, with lung metastasis, reference to CT scans rather than PETscans is important in making a carefull diagnosis. In judging the effect of preoperative chemoradiotherapy, PET-CT was suggested to be an effective diagnostic tool. In addition, PET may be a useful diagnostic tool for postoperative follow-up patients. Finally, further investigation may well be necessary in the future.

Entities:  

Mesh:

Year:  2009        PMID: 20009448

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

1.  Extraparietal or lymphatic late relapse of neoplasms: confirmation by means of EUS-FNA key for the treatment.

Authors:  Jose Luis Ulla-Rocha; Zenaida Vilar-Cao; Monica Alvarez-Martinez; Laura Salgado-Boquete
Journal:  J Gastrointest Cancer       Date:  2012-09

2.  Geographic distribution of regional metastatic nodes affects the outcome of trimodality-eligible patients with esophageal adenocarcinoma.

Authors:  Hironori Shiozaki; Rebecca Slack; Kazuki Sudo; Elena Elimova; Roopma Wadhwa; Hsian-Chun Chen; Heath D Skinner; Ritsuko Komaki; Jeffrey H Lee; Brian Weston; Manoop S Bhutani; Mariela A Blum; Jane E Rogers; Dipen M Maru; Wayne L Hofstetter; Jaffer A Ajani
Journal:  Oncology       Date:  2015-02-28       Impact factor: 2.935

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.